News

Sanofi links with Evotec to tap stem cells for diabetes care


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Sanofi links with Evotec to tap stem cells for diabetes care

 

Date: 07/08/2015

French drugmaker Sanofi is linking with Evotec to develop stem cell-based treatments for diabetes, under a deal that could earn the German biotech firm more than 300 million euros ($327 million).

Sanofi, a leading supplier of diabetes care, said on Friday the aim was develop beta cell-modulating diabetes therapies that could reduce or eliminate the need for insulin injections.

Beta cells play a key role in the development of diabetes and are destroyed by the patient's own immune system in type 1 diabetes.

For more click here

Source: Reuters

© Catalyst Innovation Portal 2019